An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).

被引：3
|
作者：
Kabbinavar, Fairooz F.
Zomorodian, Nazy
Rettig, Matthew
Khan, Faraz
Greenwald, Daniel Reif
DiCarlo, Brian
Davidson, Sheldon J.
Patel, Ravindranath
Pandit, Lalita
Chandraratna, Rosh
Sanders, Martin
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Inst Urol Oncol, Los Angeles, CA 90095 USA
[2] VA Greater Los Angeles Healthcare Syst, Dept Med, West Los Angeles, CA USA
[3] Tanslat Res Oncol US, Los Angeles, CA USA
[4] Translat Oncol Res Int, Santa Maria, CA USA
[5] Lalita Pandit MD Inc, Fountain Valley, CA USA
[6] Therapeut Inc, Santa Ana, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 04期
关键词：
D O I：
10.1200/jco.2014.32.4_suppl.169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
169
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC)
    Pinski, Jacek K.
    Schally, Andrew V.
    Tsao-Wei, Denice D.
    Dorff, Tanya B.
    Groshen, Susan G.
    Xiong, Shigang
    Quinn, David I.
    Tai, Yu-Chong
    Engel, Juergen
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] A randomized phase II, open-label study of sipuleticel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).
    Quinn, David I.
    Petrylak, Daniel Peter
    Piaczonka, Christopher Michael
    Sandler, Andrew
    DeVries, Todd
    Sheikh, Nadeem A.
    Drake, Charles G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study
    McDermott, Raymond S.
    Greene, John
    McCaffrey, John
    Parker, Imelda
    Helanova, Sylva
    Baird, Anne-Marie
    Teiserskiene, Ausra
    Lim, Marvin
    Matthews, Helen
    Deignan, Olwyn
    Feeney, John
    Thirion, Pierre G.
    Finn, Stephen P.
    Kelly, Paul J.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [34] Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
    Slovin, S. F.
    Higano, C. S.
    Hamid, O.
    Tejwani, S.
    Harzstark, A.
    Alumkal, J. J.
    Scher, H. I.
    Chin, K.
    Gagnier, P.
    McHenry, M. B.
    Beer, T. M.
    ANNALS OF ONCOLOGY, 2013, 24 (07) : 1813 - 1821
  • [35] Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey
    Ojamaa, Kristiina
    Hoimes, Christopher J.
    Vaishampayan, Ulka
    Berger, Ranaan
    Sezer, Ahmet
    Alanko, Tuomo
    de Wit, Ronald
    Li, Chunde
    Omlin, Aurelius
    Procopio, Giuseppe
    Fukasawa, Satoshi
    Tabata, Ken-ichi
    Park, Se Hoon
    Feyerabend, Susan
    Drake, Charles G.
    Wu, Haiyan
    Qiu, Ping
    Kim, Jeri
    Poehlein, Christian
    de Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [36] Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase II clinical trial
    Pan, C.
    Ghosh, P.
    Lara, P., Jr.
    Robles, D.
    Beckett, L.
    White, R. de Vere
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [37] ARN-509 IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D.
    Antonarakis, E. S.
    Shore, N. D.
    Tutrone, R.
    Alumkal, J.
    Ryan, C. J.
    Saleh, M.
    Hauke, R.
    Chow-Maneval, E.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 317 - 317
  • [38] A Phase II Trial Evaluating the Efficacy and Safety of Efavirenz in Metastatic Castration-Resistant Prostate Cancer
    Houede, Nadine
    Pulido, Marina
    Mourey, Loic
    Joly, Florence
    Ferrero, Jean-Marc
    Bellera, Carine
    Priou, Frank
    Lalet, Caroline
    Laroche-Clary, Audrey
    Raffin, Mireille Canal
    Ichas, Francois
    Puech, Alain
    Piazza, Pierre Vincenzo
    ONCOLOGIST, 2014, 19 (12): : 1227 - 1228
  • [39] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tsuchiya, Tomohiro
    Imanaka, Keiichiro
    Iwaki, Yuki
    Oyama, Ryo
    Hashine, Katsuyoshi
    Yamaguchi, Akito
    Uemura, Hiroji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (12) : 1596 - 1604
  • [40] An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
    Tomohiro Tsuchiya
    Keiichiro Imanaka
    Yuki Iwaki
    Ryo Oyama
    Katsuyoshi Hashine
    Akito Yamaguchi
    Hiroji Uemura
    International Journal of Clinical Oncology, 2019, 24 : 1596 - 1604
12345